• Recently, Medtronic announced several product milestones, including the first patient enrollment in its ENDURANCE Post-Approval Study for the Altaviva tibial neuromodulation device, the launch of its Adaptive Deep Brain Stimulation system for Parkinson’s disease in India, CE Mark clearance for the Stealth AXiS robotics and navigation platform in Europe, and FDA Breakthrough Device Designation for its Sphere-9 catheter.
• Together, these developments highlight Medtronic’s push into AI-enabled robotics, neuromodulation, and advanced cardiac ablation technologies across major global markets, broadening its presence in high-complexity, procedure-driven care.
• We’ll now examine how the CE Mark for Stealth AXiS, expanding Medtronic’s robotics footprint in Europe, may influence this investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Medtronic Investment Narrative Recap

To own Medtronic, you need to believe its broad medical device portfolio and steady innovation in higher-complexity procedures can offset slower growth pockets and margin pressure. The recent Stealth AXiS CE Mark, along with Sphere-9’s Breakthrough status, supports the case for robotics and cardiac ablation as key near term growth drivers, while execution on large product ramp ups and the Diabetes separation remains the biggest source of uncertainty rather than materially changing the immediate catalyst.

Among the latest announcements, the CE Mark for the Stealth AXiS robotics and navigation system in Europe looks most relevant, as it expands Medtronic’s presence in AI enabled spine and cranial procedures and directly ties into expectations that robotics and digital platforms can improve its growth profile and margin mix over time, if adoption and manufacturing scale up as planned.

But while these advances are encouraging, investors should also be aware that persistent margin pressure in core segments could...

Medtronic's narrative projects $40.8 billion revenue and $6.5 billion earnings by 2029. This requires 4.8% yearly revenue growth and a roughly $1.9 billion earnings increase from $4.6 billion today.

Uncover how Medtronic's forecasts yield a $108.00 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Nine members of the Simply Wall St Community currently see Medtronic’s fair value between US$93 and US$108 per share, reflecting a fairly tight cluster of expectations. Against that, the company’s heavy R&D and commercial spending, especially around robotics and cardiovascular systems, raises questions about whether new launches will translate into sufficient earnings growth, so it is worth comparing several viewpoints before deciding how compelling this story looks to you.

Explore 9 other fair value estimates on Medtronic - why the stock might be worth just $93.00!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Medtronic research is our analysis highlighting 6 key rewards that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.